Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650751 | 0.81 | CYP1A2 (0.49) | ALDH1A1TSHRKDRHPGDNT5E | |
| SCHEMBL2648823 | 0.81 | KDR (0.44) | ALDH1A1KDM4EKDRNT5E | |
| SCHEMBL2649465 | 0.78 | HPGD (0.39) | ALDH1A1TSHRTP53KDRHPGD | |
| SCHEMBL2648039 | 0.78 | KDR (0.40) | ALDH1A1KDRHPGD | |
| SCHEMBL2652084 | 0.77 | ALDH1A1 (0.44) | MAPTLMNAALDH1A1TSHRKDM4E | |
| SCHEMBL6856564 | 0.77 | ATM (0.38) | LMNAALDH1A1KDRHPGDNT5E | |
| SCHEMBL2652763 | 0.76 | RIPK1 (0.39) | ALDH1A1KDRHPGD | |
| SCHEMBL5780420 | 0.76 | KDR (0.36) | ALDH1A1KDM4EKDRHPGDNT5E | |
| SCHEMBL2647976 | 0.76 | HPGD (0.42) | LMNAALDH1A1KDRHPGD | |
| SCHEMBL7819821 | 0.74 | KDR (0.49) | ALDH1A1KDRHPGDNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | TBK1 722/4885MAPT 906/4885LMNA 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.